Drug Profile
Research programme: long-acting growth hormone receptor antagonist - DiAthegen
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator DiAthegen
- Class
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Acromegaly; Carcinoid tumour; Diabetes mellitus
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Acromegaly in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Carcinoid tumour in USA
- 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-mellitus in USA